Nasdaq:US$13.45 (+0.81) | HKEX:HK$21.40 (+2.06) | AIM:£2.21 (+0.21)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
About Us
Overview
Corporate Information
Board of Directors
Management
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
27 Jun 2022
HUTCHMED to Announce 2022 Half-Year Financial Results
Read more
1 Jun 2022
HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China
Read more
30 May 2022
Notice of Publication of 2021 Sustainability Report
Read more
2 May 2022
HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
Read more
Scientific Publications
6 Jun 2022
ASCO2022: Surufatinib in US Patients with Soft Tissue Sarcoma
Read more
6 Jun 2022
ASCO2022: A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs
Read more
12 Dec 2021
ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
Read more
3 Nov 2021
NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.